Know Cancer

forgot password

A Phase I Study of Cabazitaxel, Mitoxantrone, and Prednisone (CAMP) for Patients With Metastatic Castration-Resistant Prostate Cancer and no Prior Chemotherapy

Phase 1
18 Years
Open (Enrolling)
Metastatic Castration-resistant Prostate Cancer

Thank you

Trial Information

A Phase I Study of Cabazitaxel, Mitoxantrone, and Prednisone (CAMP) for Patients With Metastatic Castration-Resistant Prostate Cancer and no Prior Chemotherapy

This is a Phase I, open label, dose-finding, multicenter clinical trial to establish the
maximum tolerated dose (MTD) and dose limiting toxicities (DLT) of cabazitaxel (25 mg/m2 IV
q21 days) in combination with mitoxantrone (4-12 mg/m2 IV q21 days) and prednisone (5mg
orally BID) in patients with metastatic CRPC who have not undergone prior chemotherapy for
metastatic disease.

Up to five cohorts will be enrolled to determine the MTD and DLT profile of this
combination. An accelerated titration design method is being used in order to minimize the
number of patients exposed to subtherapeutic doses of mitoxantrone.

Inclusion Criteria:

1. Histologically confirmed adenocarcinoma of the prostate.

2. Progressive metastatic prostate cancer (positive bone scan or measurable disease)
despite castrate levels of testosterone (either from orchiectomy or LHRH agonist therapy).

3. Patients may have either non-measurable disease OR measurable disease

4. All patients must have a PSA ≥ 2 ng/mL.

5. Progressive disease based on any one of the following:

1. . transaxial imaging

2. . a rise in PSA

3. . radionuclide bone scan

Patients whose sole manifestation of progression is an increase in disease-related
symptoms are not eligible.

1. For patients with measurable disease, progression will be defined by the RECIST

2. For patients with non-measurable disease, a positive bone scan and elevated PSA
will be required. PSA evidence for progressive prostate cancer during or after
first-line chemotherapy consists of a PSA level of at least 2 ng/ml which has
risen on at least 2 successive occasions, at least one week apart. If the
confirmatory PSA (#3) value is less (i.e., #3b) than the screening PSA (#2)
value, then an additional test for rising PSA (#4) will be required to document
progression for the purposes of eligibility.

3. Radionuclide bone scan: new metastatic lesions

6. Testosterone < 50 ng/dL. Patients must continue primary androgen deprivation
with an LHRH analogue if they have not undergone orchiectomy.

7. ECOG Performance Status 0 -2.

8. Required Laboratory values:

1. Creatinine < 1.5 x upper limits of normal (ULN). If Cr. > 1.5 x ULN, then
calculated creatinine clearance > 40cc/min.

2. ALT and AST within normal limits

3. Absolute neutrophil count > 2,000/mm3

4. Platelets > 100,000/ mm3

5. Hemoglobin > 8.0 gm/dL

6. Total bilirubin within normal limits

9. Ejection fraction by MUGA scan or echocardiogram ≥ lower limit of
institutional normal.

10. Patients receiving hormonal therapy (i.e. any dose of megestrol acetate
(Megace), Proscar (finasteride), any herbal product known to decrease PSA levels
(e.g., Saw Palmetto and PC-SPES) other than LHRH agonist/antagonist or a stable
dose of corticosteroid from a prior chemotherapy regimen must discontinue the
agent for at least 4 weeks prior to enrollment. Progressive disease must be
documented after discontinuation of the hormonal therapy.

11. No other systemic therapies for prostate cancer within 28 days prior to
initiation of this protocol.

12. Prior radiation therapy completed ≥ 4 weeks prior to enrollment.

13. No history of radiopharmaceuticals (strontium, samarium) for prostate cancer

14. Patients must agree to use adequate contraception (hormonal or barrier
method of birth control) prior to study entry, for the duration of study
participation and for 3 months after discontinuing therapy. Should a patient's
sexual partner become pregnant or suspect she is pregnant while the patient is
participating in this study, he should inform the treating physician

15. Life expectancy > 12 weeks.

16. Age ≥ 18 years

17. Inclusion of Minorities: Men and members of all ethnic groups are eligible
for this trial.

Exclusion Criteria:

1. Patients with significant cardiovascular disease including congestive heart
failure (NYHA class III or IV), active angina pectoris or myocardial
infarction within 6 months.

2. Patients with serious intercurrent infections, or nonmalignant medical
illnesses that are uncontrolled or whose control may be jeopardized by the
complications of this therapy.

3. Patients with psychiatric illness/social situations that would limit
compliance with study requirements.

4. Patients with pre-existing neuropathy greater than CTCAE Grade 1 (motor or

5. Patients with known prior severe hypersensitivity reactions to cabazitaxel
or other agents containing polysorbate 80.

6. Patients with known active brain metastases are excluded because of their
poor prognosis. Head CT is NOT routinely required prior to enrollment.
Patients with treated, asymptomatic brain metastasis will be eligible for

7. Patients with a "currently active" second malignancy other than
non-melanoma skin cancer are excluded. [Patients are not considered to have
a "currently active" malignancy if they have completed therapy and are
considered by their physician to be at less than 30% risk of relapse.]

8. Concurrent use of moderate to strong CYP3A4 inhibitors is not allowed.

Type of Study:


Study Design:

Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Determination of the maximum tolerated dose (MTD) of the combination of cabazitaxel and mitoxantrone/prednisone as chemotherapy for patients with metastatic CRPC who have not received prior chemotherapy for metastatic disease.

Outcome Time Frame:

Participants will be followed for the duration of treatment, an expected average of 4 months.

Safety Issue:


Principal Investigator

Charles Ryan, MD

Investigator Role:

Study Chair

Investigator Affiliation:

University of California, San Francisco


United States: Food and Drug Administration

Study ID:

UCSF Protocol No. 11951



Start Date:

June 2012

Completion Date:

June 2017

Related Keywords:

  • Metastatic Castration-Resistant Prostate Cancer
  • metastatic
  • CRPC
  • prostate
  • CAMP
  • Prostatic Neoplasms



UCSF Comprehensive Cancer CenterSan Francisco, California  94115